<DOC>
	<DOCNO>NCT00705679</DOCNO>
	<brief_summary>A new approach HIV prevention currently study include use microbicides , substance kill microbe . Tenofovir disoproxil fumarate ( TDF ) emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) oral , FDA-approved , anti-HIV drug , tenofovir gel experimental microbicide . The purpose study determine safety effectiveness daily tenofovir 1 % gel compare vaginal placebo gel , safety effectiveness oral TDF oral FTC/TDF compare oral placebo prevent HIV infection among woman risk sexually transmit infection .</brief_summary>
	<brief_title>Safety Effectiveness TFV 1 % Gel , TDF Tablets , FTC/TDF Tablets Preventing HIV Women</brief_title>
	<detailed_description>It necessary monitor adherence blood level microbicides order gauge efficacy study population . Utilizing experimental microbicide ( tenofovir gel ) anti-HIV drug ( TDF , FTC/TDF ) , study measure effectiveness safety blood level three intervention three regimen give HIV uninfected woman . The expected duration participation participant range minimum 12 month maximum 38 month . Study participant randomly assign one five study group , different regimen . Group 1 participant take one TDF tablet daily one FTC/TDF placebo tablet daily . Group 2 participant take one TDF placebo tablet daily one FTC/TDF tablet daily . Group 3 participant take one TDF placebo tablet daily one FTC/TDF placebo tablet daily . Group 4 participant apply tenofovir 1 % gel vaginally daily . Group 5 participant apply tenofovir 1 % placebo gel vaginally daily . Study visit occur every 28 day enrollment . Medical history , physical exam , behavioral adherence assessment , urine blood collection , counsel occur visit . Blood also collect archived future research select visit . Pharmacokinetic study occur visit . A pap smear occur select visit . Some participant may hair sample collect optional basis study visit every 2 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Willing provide adequate locator information Sexually active , define vaginal intercourse least 3 month prior screen Agree participate research study involve drug , medical device , vaginal product duration study . Agree use effective method contraception . More information criterion find protocol . HIV infect Known adverse reaction study product Known adverse reaction latex Pathologic bone fracture relate trauma Nontherapeutic injection drug use 12 month prior screen Postexposure prophylaxis HIV exposure within 6 month prior enrollment Last pregnancy outcome 42 day less prior enrollment Gynecologic genital procedure 42 day less prior enrollment Participation research study involve drug , medical device , vaginal product 30 day less prior enrollment Currently use spermicide , interferon interleukin therapy , certain medication . More information criterion find protocol . Any significant uncontrolled active chronic disease . More information criterion find protocol . Certain abnormal laboratory value . More information criterion find protocol . Intends become pregnant 24 month enrollment Plans relocate travel away study site 8 consecutive week 24 month enrollment Urinary tract infection Pelvic inflammatory disease , STI , reproductive tract infection require treatment Grade 2 high pelvic exam find Any condition , opinion investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>